Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Supply issues

Some strengths of fluoxetine unavailable until December 2019

Fluoxetine antidepressant

Source: Dr P Marazzi / Science Photo Library

Prescribers should consider alternative preparations and/or strengths for patients who do not have sufficient supplies for the duration of the out-of-stock period

Manufacturing issues affecting the supply of the antidepressant fluoxetine mean that some strengths may not be available until December 2019, the Department of Health and Social Care (DHSC) has warned.

The supply issues affect fluoxetine 10mg capsules (Morningside Pharmaceuticals and Advanz Pharma), 30mg (Advanz Pharma) and 40mg (Advanz Pharma) capsules.

It is predicted that stocks of 10mg Advanz Pharma capsules will not be available until early December 2019, and that the 30mg and 40mg capsules will not be available until early November 2019.

The 10mg Morningside Pharmaceuticals capsules will not be available until the end of October 2019.

In a warning letter, the DHSC recommended that prescribers should identify all patients currently taking these strengths of fluoxetine and make early contact with either them or their carers to determine if their stocks will last until early November 2019.

For patients who have sufficient stocks, no repeat prescription should be issued during this period.

Prescribers should consider alternative preparations and/or strengths for patients who do not have sufficient supplies for the duration of the out-of-stock period. For example, suggested alternatives for fluoxetine 10mg capsules include fluoxetine 10mg tablets, fluoxetine 20mg/5ml oral solution, or unlicensed fluoxetine 10mg capsules. 

The DHSC said it had identified specialist importers that can source unlicensed imports, but it warned that any decision to prescribe an unlicensed medicine must consider the relevant guidance and NHS trust or local governance procedures.

The Pharmaceutical Services Negotiating Committee has advised that if a pharmacist is asked to dispense an unlicensed import, the prescription should be annotated ‘special order’ (SP) and be endorsed with the quantity dispensed; pack size; price per pack; manufacturer license number; batch number; and specials procurement fee endorsement of ‘SP’.

  • This article was amended on 30 September 2019 to replace the incorrect usage of the word ‘dose’ with ‘strength’

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20207100

Readers' comments (1)

  • Am I behind the times or should this article be talking about 'strengths of ...' rather than 'doses of'? Surely dose is the amount the patient is taking at a time which could be any combination or quantity of dosage forms as agreed with their prescriber.

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.